Real World SB4 (Etanercept Biosimilar) Use in Patients With Psoriasis: Data from the British Association of Dermatologists Biologic Interventions Register (BADBIR)

March 2020 | Volume 19 | Issue 3 | Case Reports | 316 | Copyright © March 2020

Published online February 5, 2020

Alexander Egeberg , Giampiero Girolomoni , Steven R. Feldman , Marc-Alexander Radtke , José Manuel Carrascosa , Jeehoon Ghil , Jung Won Keum , Jieun Lee , Hyoryeong Seo

aDepartment of Dermatology and Allergy, Herlev and Gentofte Hospital, Copenhagen, Denmark bSection of Dermatology and Venereology, Department of Medicine, University of Verona, Verona, Italy cDepartment of Dermatology, Wake Forest University School of Medicine, NC dDermatologikum Hamburg dermatologic practice, Hamburg, Germany eHospital Universitari Germans Trias i Pujol, Universidad Autónoma de Barcelona, Barcelona, Spain fSamsung Bioepis Co., Ltd., Incheon, Republic of Korea

Effectiveness was assessed in patients who had PASI and DLQI both at baseline and at 6 months. 48 patients were categorized by their PASI score at baseline (<10 or ≥10; Figure 2A). For 20 patients with baseline PASI <10 (mean PASI, 3.2±2.7), disease activity was maintained at 6 months (mean PASI, 3.2±2.6), with mean PASI reduction of 0.0±2.3. For 28 patients with baseline PASI ≥10 (mean PASI, 15.7±3.8), mean PASI at 6 months was 5.0 ± 6.2 with mean PASI reduction of -10.7±6.6.

For 19 patients with baseline DLQI ≥10 (mean DLQI, 18.9±5.1), mean DLQI at 6 months was 6.5±7.2 with mean DLQI reduction of -12.4±7.1 (Figure 2B). For 3 patients with baseline DLQI <10 (mean DLQI, 2.0±2.0), mean DLQI at 6 months was 1.3±2.3 with mean DLQI reduction of -0.7±3.1.


SB4 was effective in patients with psoriasis in a real-life clinical setting. 16 out of 189 patients (8.5%) were previously exposed to biologic and among them, 10 patients were switch patients from reference etanercept. This transition was mainly non-medical switch. Reasons for discontinuation appeared similar to what would be expected for the reference etanercept.

Kaplan Meier analysis showed that the discontinuation rate of SB4 at 12 months was 24.4%. This is comparable to a previously reported discontinuation rate of reference etanercept in BADBIR, which was based on biologic naïve patients.13 In our study, most patients were biologic naïve and the patient demographics are similar to the etanercept cohort except for baseline PASI. Baseline PASI at the iniation of SB4 was 11.6±7.3 while baseline PASI for etanercept cohort at BIADBIR was 15.4±7.9. The discon-